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Background and objectives: Inadequate minority participation in clinical research can threaten the
applicability and strength of scientiﬁc ﬁndings. Previous research suggests that trial participation rates
are lowest among Asian Americans, compared to other groups. This study explored barriers to clinical
research participation among elder Chinese living in Houston, Texas. Additionally we administered the
Trust in Medical Researchers Scale (TIMRS), used previously in researching trust in medical researchers
as related to research participation.
Design: In this mixed methods study, a semi-structured interview, including the TIMRS were adminis-
tered to 30 adults of Chinese ancestry aged 50 years or older recruited from a Chinese community center.
Interviews were conducted in English, Mandarin and Cantonese and independently coded and analyzed
using thematic content analysis. TIMRS scores were calculated for participants.
Results: Participants were 70% female, 70% were 60 or elder, all were foreign born and on average lived in
the US for 21.8 years. Participants perceived risks to research participation and preferred language
concordant research staff. Interviewees were more willing to participate if they perceived personal and
community health-related beneﬁts. The overall TIMRS score was 23.9 (±5.0), lower than the overall
TIMRS for Whites in a previous study (P < 0.001).
Conclusions: The barriers and facilitators to research participation conﬁrmed previous research among
Asians. Our participant TIMRS scores were consistent with decreased levels of trust observed in the
original TIMRS study for African Americans as compared and lower than Whites. Employing strategies
that utilize language concordant staff who build trust with participants may aid in recruiting elder
Chinese, especially if the research is personally relevant to those being recruited.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Underrepresentation of racially and ethnically diverse groups in
medical research is an ongoing problem [1e4]. Participant diversity





r Inc. This is an open access articlemore broadly and to analyze responses to experimental in-
terventions received by different racial and ethnic groups [5e9].
When participants lack diversity, researchers are limited in their
ability to draw scientiﬁcally rigorous conclusions about the efﬁcacy
of experimental interventions. The U.S. Census Bureau projects that
the proportion of the population over age 65 will continue to in-
crease and the population in general will continue to increase in
diversity [10]. With Medicare bearing the health care costs for most
of those over age 65, interventions to maintain or improve the
health of this population are increasingly important. The propor-
tion of elder Asians in the US is also expected to increase [11].under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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debilitating diseases including chronic hepatitis B, HIV/AIDS, and
tuberculosis [12]. Currently, Asian Americans experience higher
rates of morbidity and mortality from liver and stomach cancer
when compared to non-Hispanic whites [13]. Despite the disease
burden, clinical trial participation rates among Asians were re-
ported to be lowest compared to other racial and ethnic minorities
[14,15].
In general, medical researchers often confront challenges when
recruiting minority participants, especially elder adults [16].
Numerous studies have reported barriers to enrollment including
lack of participant trust [17e20], ineligibility due to comorbid
conditions [21,22], and lack of information about clinical study
opportunities [23]. We reviewed the extant research examining
barriers and facilitators for minority participation. The majority of
studies have focused on barriers among African Americans relative
to other racial and ethnic groups [3,4,24,25].
The literature gives some insight as to why there is low partic-
ipation and suggests that Asian have similar barriers to trial
participation as other ethnic groups such as fear of side effects from
experimental treatments [26], limited knowledge about clinical
research [27e29], language barriers [27,30,31], and mistrust [28]. A
2005 study reported that, compared to non-Asians, elder Asian
immigrants were more inﬂuenced to participate in research by
children, landlords, physicians and the media [32]. Personal gain
[31], involving the patient’s family in the decision making process
[27], and receiving a recommendation to participate by trusted
relatives or family physicians [27] have all been identiﬁed as
possible motivators for research participation among Asians. Few
studies take the Asian population’s heterogeneity in to account [33]
or characterize facilitators and barriers exclusively for the Chinese
population, the largest Asian subgroup in the U.S. [28,29].
We explored the patient perspective on willingness to partici-
pate in medical research among a sub-group of elder Chinese living
in Houston, TX. We addressed the patient perspective via in-depth
interviews supplemented by a psychometrically validated self-
report scale. The present study is the ﬁrst to administer the Trust
in Medical Researchers Scale (TIMRS) in this population. This vali-
dated scale has examinedmistrust inmedical researchers in African
American andWhite community residents [20]. The scale measures
the impact of researcher honesty and participant deception, two
key domains in researchers mistrust. Since much of the body of
evidence exploring mistrust in minority populations is over-
whelmingly qualitative in nature we wanted to supplement our
qualitative study with a scale to quantify trust in medical re-
searchers in the elder Chinese population.
2. Methods
2.1. Design
This study applied a mixed methods approach (in-depth in-
terviews and a quantitative scale). A qualitative research approach
was selected as a useful framework for studying patients’ beliefs
and willingness to participate in medical research [34]. Qualitative
research explores research participation from the participant
perspective and generates theories to be tested further in more
traditional study designs. Qualitative research cannot determine
causal relationships [35]. The qualitative analyses of the in-depth
interviews were supplemented with quantitative data from the
TIMRS.
2.2. Participant recruitment
Participant recruitment was facilitated by an establishedrelationship between the University of Texas Health Science Center
at Houston (UTHealth) and the Houston (TX) Chinese Community
Center, which provides a variety of services ranging from childcare
to senior services. Community center staff were familiar with reg-
ular visitors to the center so they recruited a purposive sample of 30
participants based on the study eligibility criteria, i.e., of Chinese
ancestry and aged 50 years or older. Sample size was determined
based on qualitative research employing semi-structured in-depth
interviews to achieve saturation of themes [36] and develop the-
ories for future testing. The participants were speciﬁcally recruited
from programs oriented towards the elder population such as the
Adult Day Program and the Senior Companionship Program. This
age group was selected to gain more information about this Asian
group’s willingness to participate in research evaluating
treatments.
2.3. Study instruments
The research project received approval through the UT Health
Committee for Protection of Human Subjects (HSC-SPH-11-0608).
The interview guide was developed in English based on previous
research that studied knowledge and awareness about the goals of
medical research; trust of health care providers and the health care
system; and attitudes toward volunteering in research [20,37e39].
The interview guide included three open-ended questions about
the participant’s knowledge and awareness of medical research.
The remaining ﬁve questions asked the participant to rate on a 10-
point scale their willingness to participate in a hypothetical clinical
trial within the next three months where 10 represented very likely
and 0 represented not at all likely. Speciﬁcally, we asked whether
compensation, free transportation, ﬂexible clinic hours, Asian study
staff, native language, or translation services increased their will-
ingness to participate. We also administered the TIMRS to partici-
pants [20] a validated scale measuring trust in medical researchers.
Items on TIMRS can be separated into two subscales: participant
deception (items 1e6) and researcher honesty (items 7e12).
Participant deception items relate to the participant’s beliefs about
being deceived or misled by medical researchers. The researcher
honesty subscale relates to participant’s beliefs about the honesty
of the researchers in explaining aspects of clinical trial participa-
tion. The TIMRS scores and subscale scores range from 0 to 48 with
higher scores indicating a greater level of trust in medical re-
searchers. A Chinese graduate student translated the interview
guide and the TIMRS into Chinese. A different Chinese student,
unfamiliar with the project, back translated the instruments into
English. We did not ﬁnd discrepancies between the forward and
back translations. The interview guide and TIMRS also underwent
brief cognitive pretesting prior to use and no problems were noted
[40].
2.4. Procedures
The Chinese graduate student that translated the interview
guide also conducted interviews in Mandarin. A second Chinese
graduate student was hired to conduct interviews in Cantonese.
Two non-Chinese students and a non-Chinese study coordinator
conducted the English interviews. All interviewers were trained in
qualitative interview methods by an experienced qualitative
researcher. Participants were read a consent form and provided
verbal consent prior to the beginning of the study. The 20e30-min,
in-person interviews were conducted in a private room at the
community center.
The TIMRS was administered after the qualitative questions.
Participants were read each question aloud and asked to point to a
card indicating their response. The scale items were answered on a
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1 ¼ strongly disagree to 5 ¼ strongly agree. The participants were
given the option to interview in Mandarin, Cantonese or English.
Seventeen interviews were conducted in Mandarin, 11 in English
and two in Cantonese. All interviews were digitally recorded, and
notes were made. Participants were compensated with a $20
Walmart gift card.
2.5. Data analysis
Interviews were professionally translated (if non-English) and
transcribed by an outside company. All transcripts were indepen-
dently coded by the ﬁrst and second authors using thematic con-
tent analysis. Themes were not developed a priori. Codes were
categorized into sub-themes, identiﬁed in the interview questions,
along with deﬁnitions and supporting quotes. Both investigators
developed separate codebooks and, through discussion, reached
consensus on themes that best illustrated the ideas communicated
in the interviews. We used ATLAS.ti software version 7 for coding
and the Consolidated Criteria for Reporting Qualitative Research
(COREQ) to present the qualitative results [41,42]. The TIMRS data
were analyzed using SAS software version 9.3 [43]. Three scale
scores were calculated from the TIMRS including overall trust in
medical researchers, participant deception and researcher honesty.
The details on how to calculate scale scores are reported elsewhere
[20].
We compared the mean overall trust scores and trust score
subscales for our elder Chinese participants to those reported by
White and African American participants in the original TIMRS scale
development study [20] using separate one-way analyses of variance
(ANOVAs). In the presence of a signiﬁcant one-way ANOVA (giving
us weak protection of alpha) we planned two, 2-sample t-tests to
compare the mean trust scores of our participants separately to
scores fromWhite and African Americans as reported in theMainous
study [20]. We used Bonferroni adjusted p-values of 0.025 to adjust
for the two comparisons within the overall trust scale score or sub-
scale scores. We also ran a logistic regression model to examine the
association between our participants’ overall trust score and their
dichotomized likelihood of participation in future medical research
(0e3, 4e10) adjusting for any covariates signiﬁcant at the 0.2 level
[44]. We chose 0.2 to adjust for any variables weakly associated with
likelihood of participation. Years in the United States was collected as
a continuous variable. Other covariates were collected as binary
(gender) or as categories. Because our sample size was small and
some categories were sparse we dichotomized the two categorical
covariates, age group [50e59, 60þ] and education [high school or
less, some college or more].
3. Results
A total of 30 Chinese participants born outside of the U.S. were
interviewed, of whom 21 (70%) were female. The majority of par-
ticipants (70%) were 60 years or older and on average reported
living in the United States for 22 years (s.d.13.29). Almost half of the
participants (46%) held a college or advanced degree, 23% had some
college education, 20% completed high school, and only 10% re-
ported some high school or less. The majority of participants re-
ﬂected a general but limited understanding of medical research and
clinical trials. When asked how theywould deﬁnemedical research
to a friend, most participants acknowledged that medical research
was a method to advance medicine, to help people, and to develop
treatments. When asked about past trial participation, three re-
spondents reported experience with medical research projects.
When probed about their research experience, only one participant
described an actual research protocol.3.1. In-depth qualitative interviews
Three themes emerged from the in-depth qualitative in-
terviews; negative perceptions of research as inherently risky;
importance of language concordance between study staff and
participants; and beneﬁts gained from participation. Quotes from
the participants are used to illustrate the themes.
In general, approximately two-thirds of our participants
expressed concerns about participating in medical research. Their
primary concern appeared to be avoidance of risk. Concerns about
safety, side effects, the uncertainty of experimental treatments, and
invasive study procedures were expressed during the interviews.
Our participants deﬁned risk as doing harm and particular concerns
were identiﬁed about studies that used radiation, x-rays, surgical
technologies, or experimental drugs. Participants were explicit
about the kinds of risks and the resulting side effects.
“The ﬁrst thing to consider is safety reasons. I feel that it’s important
that being a subject doesn’t cause side effects or whatever. I think I
need to be guaranteed and there needs to be a little bit of conﬁrmed
data. That is, at our age, the ﬁrst thing is, of course, health. So I think
we need to ﬁrst guarantee that there is no harm participating in
this.”
Additionally, participants viewed procedures that introduced a
foreign substance or object to be invasive. Pharmaceutical drugs
were also described as foreign substances and presumed to bemore
dangerous than natural ones. One participant said
“Deciding factor is anything that do with man-made drugs, that I
will not participate. If it is about nutrition or nutrients, that I will
think about it. But not man-made drugs, I don’t believe in man-
made drugs.”
Some participants seemed to base their fears of participation on
reports from others, or beliefs they had acquired about the relative
dangers of medical procedures.
“I got to see whether that thing is harmful. Because we don’t know
exactly howmedical [medicine] work, but we have heard too many
things, like x-ray is harmful to you, if you take too many mam-
mograms in one year, it will be harmful. So you will think about it if
you don’t know the harms.”
Some participants would only consider enrolling if their illness
could not be ameliorated with a medication that has been approved
for public use for a period of time or a treatment for which tangible
results are visible. Perceived risks operated as a hypothetical barrier to
enrolling in research studies. Participants perceived invasive studies,
non-natural therapeutic agents, and possible side effects as risky and
as a result, made them less likely to participate in medical research.
Respondents consistently reported that speaking the same lan-
guage as the research staff was important. Willingness to participate
in studieswas clearly facilitated by language concordance.While few
participants speciﬁcally stated that they preferred to speak Chinese,
the majority noted that staff who spoke their language would make
participation more likely in other studies. Speaking the same lan-
guage made respondents feel comfortable, because, for many, En-
glish was their second language. Participants believed that fewer
misinterpretations occurred when the same language was spoken
and, in some cases, when there was ethnic concordance.
“I can communicate with Asian health care workers, I can explain
my conditions in more details and I can hear what the doctors say
more clearly as well.”
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Especially the medication’s name, illness name, diseases, very
difﬁcult to understand. If there is Asian people over there, they
translate it right away, it saves a lot of trouble.”
Interestingly, for some participants, as long as study staff spoke
the same language (either Mandarin or Cantonese) their race/
ethnicity did not matter. When probed further about other factors
that would facilitate enrollment, respondents named clear
communication as more important than staff demographics. For
some respondents, translators facilitated participation for the same
reasons. Participants felt that translators helped them understand
often-difﬁcult medical terminology, although a few thought it too
cumbersome to arrange for translators during an ofﬁce visit. Others
were concerned that translators may not reliably express what the
participant was trying to convey.
Participants expressed a greater willingness to enroll in studies
if they perceived personal or community health-related beneﬁts
from participation. Many reported that research must address the
participant’s health status, the well-being of family/loved ones, or
the broader community in order for them to strongly consider
participation. This quote illustrates how willing they are
“Willingness depends on what disease I have. For example let’s say
you research a particular aspect and if I know this is a disease that I
have, I will go.”
A few participants reported altruistic motivations for consid-
ering trial enrollment. They commented that even if the study was
not personally relevant, it would advance the body of science so
that cures and treatments could be made available in the future for
all people. Among those endorsing altruistic motivations for
participating in research, most respondents had positive expecta-
tions for the knowledge gained from trials. The need for personal
gain was not apparent; indeed, beneﬁts for unknown others were
also seen as a beneﬁt of participation.
“If I take the trial, and maybe later on it will beneﬁt a lot of
people. It doesn’t matter what happens to me, but I want to let
people have the good result.”
3.2. Trust in Medical Researchers Scale ﬁndings
The quantitative portion of the study examined the level of trust
in medical researchers among the elder Chinese participants living
in Houston. The overall TIMRS score and sub-scale scores for our
participants are reported in Table 1. Table 1 also gives the TIMRS
scores from the original study [20].
When participants were asked about their likelihood of partici-
pation in medical research within the next 3 months, 70% of the
participants responded that they had some likelihood of participa-
tion. We also examined the association between the overall TIMRS
score and likelihood of future participation using a logistic regression
model. We found that after adjusting for age and number of years
living in the United States, participants with higher overall trust
scores were more likely to participate in a research trial within the
next three months; (OR ¼ 1.58, 95%CI 1.01e2.48). See Table 2.
4. Discussion
Our study used a mixed methods approach to measure trust in
medical research and researchers among an elder purposive sam-
ple of Chinese Americans living in Houston and to examine theirwillingness to participate in clinical trials. Although our study
conﬁrmed previous ﬁndings from Chinese groups [28] regarding
the importance of language concordance and personal beneﬁts this
study extended those ﬁndings by emphasizing the importance of
trust in research participation. Language issues have been identi-
ﬁed as a recurrent barrier to research participation by Chinese and
Latino samples [27,39,45]. When probing our participants about
facilitators to research participation, they clearly expressed a
preference for language-concordant interactions with potential
research personnel. Translators were seen as a less desirable
alternative than research staff who spoke their language. The issue
of racial concordance among our participants seemed considerably
less important than language concordance, which has been an issue
in previous samples using different minority populations [46,47].
Among our participants, motivation to participate appeared to
be closely linked to participants’ perceptions that the research ac-
tivity would provide a beneﬁt to them personally, to their families,
or to the larger overall Chinese community. This is consistent with
some previous research on Chinese and African Americans [28,48].
However, when asked about facilitators to research participation
our participants did not appear to mention free screening or
ﬁnancial compensation, as has been seen in Latino samples and
other Asian groups [24].
In line with previous research ﬁndings [39,48,49], our partici-
pants expressed perceived risks including concerns about the ef-
ﬁcacy and safety of treatments, as barriers to participation. The
ﬁndings of the importance of trust dovetail with the construct of
perceived risks and bring to the fore the importance both
communication and trust between the potential participant and
the medical researchers. African Americans tended to cite the
Tuskegee syphilis study, where non-minority researchers inten-
tionally withheld treatment for syphilis from African American
male participants, as the basis for their mistrust [49]. Latinos re-
ported fears of inadequate safeguards and underqualiﬁed physi-
cians (perhaps based on their experiences in their native countries)
[39,50]. Participants in our study believed the types of procedures
(invasive/x-ray related interventions) and pharmaceutical (as
opposed to “natural”) chemical agents conferred excessive risk for
side effects. Participants trusted agents, mainly peers or family, to
provide accurate information about medical research. Researchers,
however, need to persuade participants that they were not going to
be harmed in the name of science. Without such reassurance, our
participants were less willing to engage in research.
Finally, although mistrust of research and researchers was not
explicitly stated by the respondents, the comments about risk and
corresponding protection of subjects implicitly suggested it. This
concern was reinforced by the low TIMRS overall scores on trust in
medical researchers. Interestingly, the trust scale scores reported
by our participants are similar to the overall trust score of 21.1 re-
ported by African Americans in a study by Mainous et al. [20] and
lower than the Whites in that study. The study by Diaz et al. [51]
reported an overall trust score of 26.5 among African American
college students which was slightly higher than the trust scores
reported by our participants. These ﬁndings point to similar levels
of trust in medical researchers by these two minority groups. The
low trust scores found may help explain the concerns expressed by
participants regarding research risks. Participants were more
willing to participate in studies testing efﬁcacious drugs, such as
antibiotics, but less willing to consider studies investigating new
therapeutic agents. As was expected when examining the associa-
tion between trust in researchers and the likelihood of future
participation, participants with higher levels of trust were more
likely to state that theywould participate in a research studywithin
the next three months. Additionally, while a high proportion of our
study participants said they would participate in a clinical trial if
Table 1
Comparison of the overall Trust in Medical Research Scale (TIMRS) and sub-scale scores between the current study of Asians and the previous study of African Americans and
Whites*.
Current Study Mainous Study Comparison
(Current Study vs. Mainous Study)
Trust Scores Chinese African American White Chinese vs. African American** Chinese vs. White**
Mean ± SD (N ¼ 30) (N ¼ 105) (N ¼ 319) P-Value P-Value
Overall Trust 23.9 ± 5.0 24.1 ± 6.9 28.7 ± 5.6 0.86 <0.001
Researcher Honesty 26.7 ± 7.3 26.3 ± 7.7 29.7 ± 6.1 0.80 0.01
Participant Deception 21.1 ± 7.5 22.0 ± 7.6 27.8 ± 6.3 0.57 <0.001
* All P-values obtained from ANOVAs were <0.001.
** P-values were obtained from 2-sample t-test between Chinese and White or African American.
Table 2
Association of overall trust in medical researchers and the likelihood of participation in a clinical trial within the next three months.
Covariates Beta SD P-value Adjusted OR 95% CL
Overall trust score 0.46 0.23 0.05 1.58 1.01e2.48
Age (60 þ vs. 50e59) 2.44 1.26 0.05 0.01 <0.001e1.05
Number of years living in the US 0.06 0.05 0.20 1.06 0.98e1.16
Note: The outcome variable (willingness to participate) was modeled as likely to participate in a future clinical trial within the next three months (Y ¼ 1).
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an overestimation of actual study participation.
4.1. Limitations
As with all studies, our interpretations of the data are con-
strained by several factors. We had limited involvement in research
subject selection, which could have resulted in selection bias by the
community center staff. We had no knowledge of the current
health status of the participants and did not elicit this information.
It is likely that our participants were recruited from a relatively
health population since they were able to attend activities at the
Houston Chinese Community Center. Our study questions could
have been more salient to those who were ill, which may have
inﬂuenced the responses about potential participation in clinical
trials. Because our participants were elder and all lived in Houston,
we cannot generalize to younger Chinese adults or to elder adults
living in other geographic areas. In addition, the use of inexperi-
enced, although trained, graduate students as interviewers may
have affected the quality and consistency of the interviews; how-
ever, the interview guide was designed to minimize these factors. It
is also possible that the standardized order of the questions might
have introduced some social desirability bias by priming partici-
pant responses.
5. Conclusions
Asians are under-represented in research studies [15,54e57], as
are most minority groups [14,58,59]. Improved understanding of
motives to participate in research across minority groups may aid
researchers in tailoring recruitment plans to help redress this
under-representation. Currently, RECRUIT (Randomized Recruit-
ment Intervention Trial), a recruitment intervention to increase
minority participation in clinical trials, is being tested in four ran-
domized clinical trials across the United States. Study ﬁndings were
used to inform the patient enrollment strategies used in RECRUIT.
Speciﬁcally, the consistency of ﬁndings on trust in medical re-
searchers reinforced our ﬁnding from studies of other minorities
[20] and the importance of building trusting relationships with
potential minority participants. Building a solid base of information
about motivators and barriers to research participation by an
under-represented minority group could further inform medicalstudy design and recruitment strategies. Given the limited
evidence-based approaches to enrolling Chinese participants, we
must rely on the authentic voices that describe what would
encourage study participation. In this way, researchers can be more
economical and targeted with their resources to engage this pop-
ulation and use this information to develop more rigorous trials of
approaches to encourage minority enrollment.
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